December 11, 1990

TO:

Drs. Burzynski

CC:

Rick Jaffe

FROM:

Le Trombetta

RE:

Dvorit Samid, PhD

When I called Dvorit today to let her know about the postponement of the Board hearing and the news from the USSR, she told me that her chairman put her "on trial" last Friday. He "demanded to know" what she's doing and requested her to do a seminar. She said it was very well received by the majority attending, but there were one or two detractors who tried to "kill me." They asked "Are you sure it's going to work?" "It's so high risk, why do it?" Very emotional.

The chairman's reaction was, "Interesting seminar." He's positive but very cautious. He's constantly afraid she's going to get his department in trouble. More and more people are seeing the Oncology News article. He's told her to make certain that her name doesn't show up in anything else that's not a scientific journal. I asked her if that means that I should tell the AMA reporter not to call her. She said, "yes." She doesn't want to speak to anyone with the media until the end of January at which time she hopes to be in better circumstances.

The Italians are still calling her once a week, sometimes once every 2 weeks. They are withholding her money until they get a "final" report from her - but they keep demanding more. They refused to pay her expenses (\$500) involved last March in coming from Geneva to Rome. When she asks for their reaction to what she's sent them, which she believes is solid and complete, they tell her, "we're waiting for our 'experts' to evaluate it." She said she's met their experts and they have no background to evaluate her work. When they couldn't duplicate the preclinical work, 13 months ago she gave them her protocol. Their experts are still having difficulty just setting up the experiment. Sigma Tau claims they'll make their decision by February.

One other story from her Athens conference: the head of an Egyptian hospital approached her and commended her for her work. He explained that urine has played an important part in medicine throughout their history, and he would like his hospital to be involved with clinical trials once the FDA has approved the treatment for trials. (Do you think Roger Schultze might like to see Egypt?)

DVorit would like to communicate with Prof. Rafes if at all possible once clinical trials get under way. She's interested in any data we can give her from all clinical work. She is currently working on her paper on antineoplastons.

January 10, 1991

Drs. B.

When I hadn't heard from Dvorit, I called her today and again left a message on her machine. When she called, she explained that she's "exhausted mentally and physically", that she's been "swimming in politics" recently. They've come down on her hard, both "in house" as well as outside. Yesterday she was in meetings for 12 hours, followed by more meetings today. She said she's fighting for her career, "when this is over I will either end up out of science totally, or in, with very strong support...and it may not be sorted out until March."

The people who are supporting her now have told her to be very careful. Supporters and detractors alike have told her to take two words out of her vocabulary: antineoplastons and Burzynski. She told me "It provokes such strong emotions in people."

Several months ago she told me that she was submitting a paper on antineoplastons and she was starting at the top with the most prestigious peer reviewed journal in this country. Today she told me that the paper was accepted, and then "thrown out at the last moment because of the political issues." It was done by phone; they would not give it to her in writing. She said that this issue "keeps coming back in my face again and again."

She said that she can't imagine how Dr. Burzynski has survived this because now she's getting it "full force." But she's not quitting. She told me, "The bottom line is this. He knows what he is doing. Through simple science without mentioning those two unmentionable words, my data will go out. We just have to be very smart right now, not stubborn, but smart and careful."

She was under the impression that the Berlin conference was in May and had already decided it was not possible because she must go to Finland in May. If it's in June, there's a chance she can go but she can't commit until her situation is stronger. She knows for certain that she would never be able to present in a special session entitled Antineoplastons. If she presents, she can not even use the term.

She brought up again something that she said she discussed with you in Geneva. She felt that because the Geneva session on Antineoplastons was a session by itself, it didn't have the attendance it should have. Regardless of what happens to her, she strongly suggests that you present to the general session so that you'll have a larger audience.

She would like to talk to you tomorrow afternoon. If you're not able to call her, you could reach her this weekend at home.

